Overview of Challenges of Evaluating ADFs in the Community
Public Deposited
- Last Modified
- September 26, 2022
- Creator
-
Dasgupta, Nabarun
- ORCID: 0000-0002-4098-605X
- Affiliation: Injury Prevention Research Center
- Abstract
- Dr. Nabarun Dasgupta presents as the invited Guest Speaker at the US Food and Drug Administration Advisory Committee on the 10 year evaluation of OxyContin reformulation. Epidemiologic considerations on evaluation of abuse deterrent formulations are presented. Presented June 10, 2020 at the Joint Meeting of the Drug Safety and Risk Management Advisory Committee (DSARM) and the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-10-11-2020-joint-meeting-drug-safety-and-risk-management-advisory-committee-and-anesthetic
- Date of publication
- September 10, 2020
- Keyword
- Subject
- DOI
- Identifier
- Resource type
- Rights statement
- In Copyright
- Language
Relations
- Parents:
- In Collection:
This work has no parents.
Items
| Thumbnail | Title | Date Uploaded | Visibility | Actions |
|---|---|---|---|---|
|
|
202009-10-11-GuestSpeaker-Dasgupta.pdf | 2022-09-26 | Public | Download |